General Information of Drug (ID: DMB2NP8)

Drug Name
T-1249 Drug Info
Synonyms Tifuvirtide; Peptide T1249; UNII-M6W86MD258; M6W86MD258; 251562-00-2; Tifuvirtide [INN]; T 1249; DB05413; 111997-EP2298761A1; 111997-EP2272516A2
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Phase 1/2 [1]
Cross-matching ID
PubChem CID
16130644
CAS Number
CAS 251562-00-2
TTD Drug ID
DMB2NP8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Enfuvirtide DM7YPM1 Human immunodeficiency virus infection 1C62 Approved [3]
Sifuvirtide DMMIWCE Human immunodeficiency virus infection 1C62 Phase 3 [4]
ITV-1 DMCJX79 Human immunodeficiency virus infection 1C62 Phase 2 [5]
MaC46/M87o DMIRG15 Human immunodeficiency virus-1 infection 1C62 Phase 1/2 [6]
Multi-envelope HIV vaccine DMAGCHE Human immunodeficiency virus infection 1C62 Phase 1 [7]
Combinectin DMTLP1N Human immunodeficiency virus infection 1C62 Phase 1 [8]
Gp41 HIV-1 vaccine DM9JV80 Human immunodeficiency virus infection 1C62 Phase 1 [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Glycoprotein 41 (HIV gp41) TTG90S6 ENV_HV1H2 Inhibitor [2]

References

1 ClinicalTrials.gov (NCT00048217) A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102. U.S. National Institutes of Health.
2 HIV entry inhibitors in clinical development. Curr Opin Pharmacol. 2002 Oct;2(5):523-8.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.J Biol Chem.2012 Feb 24;287(9):6788-96.
5 Clinical pipeline report, company report or official report of Immunotech Laboratories.
6 DOI: 10.1038/mt.sj.6300124
7 An assessment of the role of chimpanzees in AIDS vaccine research. Altern Lab Anim. 2008 Sep;36(4):381-428.
8 Clinical pipeline report, company report or official report of ViiV Healthcare.
9 Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617.